Professor David Owens
Telephone: (01792) 602208
Email: JavaScript is required to view this email address.


  1. Monnier, L., Colette, C., Schlienger, J., Bauduceau, B., R Owens, D., Owens, D. Glucocentric risk factors for macrovascular complications in diabetes: Glucose ‘legacy’ and ‘variability’-what we see, know and try to comprehend Diabetes & Metabolism
  2. Ceriello, A., Monnier, L., Owens, D. Glycaemic variability in diabetes: clinical and therapeutic implications The Lancet Diabetes & Endocrinology
  3. Owens, D., Landgraf, W., Frier, B., Zhang, M., Home, P., Meneghini, L., Bolli, G. Commencing insulin glargine 100 U/mL therapy in individuals with type 2 diabetes: Determinants of achievement of HbA1c goal less than 7.0% Diabetes, Obesity and Metabolism 21 2 321 329
  4. Owens, D., S Bailey, T., Fanelli, C., Yale, J., Bolli, G., Owens, D. Clinical relevance of pharmacokinetic and pharmacodynamic profiles of insulin degludec (100, 200 U/mL) and insulin glargine (100, 300 U/mL) – a review of evidence and clinical interpretation Diabetes & Metabolism
  5. Frier, B., Landgraf, W., Zhang, M., Bolli, G., Owens, D. Hypoglycaemia risk in the first 8 weeks of titration with insulin glargine 100 U/mL in previously insulin-naive individuals with type 2 diabetes mellitus Diabetes, Obesity and Metabolism

See more...


  • Self Monitoring of Blood Glucose (SMBG) in non insulin treated type 2 diabetes (awarded 2019)

    Other supervisor: Prof David Owens
    Other supervisor: Prof Stephen Luzio